(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 June 2005 (30.06.2005)

PCT

(10) International Publication Number
WO 2005/058873 A1

(51) International Patent Classification[7]: C07D 401/14, A61K 31/4184, C07D 417/14, A61P 11/00, 31/12

(21) International Application Number:
PCT/EP2004/053606

(22) International Filing Date:
20 December 2004 (20.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03104802.8 18 December 2003 (18.12.2003) EP
60/566,835 30 April 2004 (30.04.2004) US

(71) Applicant *(for all designated States except US)*: **TIBOTEC PHARMACEUTICALS LTD.** [IE/IE]; Little Island, Co Cork (IE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BONFANTI, Jean-François** [FR/FR]; 4 bis Route Nationale, F-27430 Andé (FR). **ANDRIES, Koenraad, Jozef, Lodewijk** [BE/BE]; Oosteneinde 9, B-2340 Beerse (BE). **JANSSENS, Frans, Eduard** [BE/BE]; Tinstraat 79, B-2820 Bonheiden (BE). **SOMMEN, François, Maria** [BE/BE]; Langenberg 49, B-2323 Wortel (BE). **GUILLEMONT, Jerôme, Emile, Georges** [FR/FR]; 51bis, route de Muids, F-27430 Andé (FR). **LACRAMPE, Jean, Fernand, Armand** [FR/FR]; 15, chemin du Pont de l'Arche, F-76240 Le Mesnil-Esnard (FR).

(74) Agent: **WANTE, Dirk**; Tibotec-Virco Comm. VA, Generaal De Wittelaan L 11B 3, B-2800 Mechelen (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ,*

[Continued on next page]

(54) Title: PIPERIDINE-AMINO-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION



(I)

(57) Abstract: The present invention concerns piperidine-amino-benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula (I) their prodrugs, *N*-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms wherein Q is C_{1-6}alkyl optionally substituted with trifluoromethyl, C_{3-7}cycloalkyl, Ar^2, hydroxy, C_{1-4} alkoxy, C_{1-4}alkylthio, Ar^2-oxy-, Ar^2-thio-, $Ar^2(CH_2)_n$oxy, $Ar^2(CH_2)_n$thio, hydroxycarbonyl, aminocarbonyl, C_{1-4}alkylcarbonyl, Ar^2carbonyl, C_{1-4}alkoxycarbonyl, $Ar^2(CH_2)_n$carbonyl, aminocarbonyloxy, C_{1-4}alkylcarbonyloxy, Ar^2carbonyloxy, $Ar^2(CH_2)_n$carbonyloxy, C_{1-4}alkoxy carbonyl$(CH_2)_n$oxy, mono- or di(C_{1-4}alkyl)aminocarbonyl, mono- or di(C_{1-4}alkyl)-aminocarbonyloxy, aminosulfonyl, mono-odi(C_{1-4}alkyl)aminosulfonyl or a heterocycles selected from the group consisting of pyrrolidinyl, pyrrolyl, dihydropyrrolyl, imidazolyl, triazolyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, pyridyl and tetrahydropyridyl, wherein each of said heterocycle may optionally be substituted with oxo or C_{1-6}alkyl; G is a direct bond or optionally substituted C_{1-10} loalkanediyl; R^1 is Ar^1 or a monocyclic or bicyclic heterocycle; one of R^{2a} and R^{3a} is C_{1-6} salkyl and the other one of R^{2a} and R^{3a} is hydrogen; in case R^{2a} is different from hydrogen then R^{2b} is hydrogen or C_{1-6}alkyl, and R^{3b} is hydrogen; in case R^{3a} is different from hydrogen then R^{3b} is hydrogen or C_{1-6}alkyl, and R^{2b} is hydrogen; t is 1, 2 or 3; Ar^1 is phenyl or substituted phenyl; and Ar^2 is phenyl or substituted phenyl. It further concerns their preparation and compositions comprising them, as well as their use as a medicine.

WO 2005/058873 A1

NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations*

— *of inventorship (Rule 4.17(iv)) for US only*

Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.